BioCryst Pharmaceuticals (NASDAQ:BCRX) has established an expanded access program for oral once-daily berotralstat for patients with hereditary angioedema
(HAE), an inherited disorder characterized by recurrent episodes of
severe swelling, usually in the limbs, face, intestinal tract and
airway.
Under the program, doctors may request the investigational drug for HAE patients who do not have access via a clinical trial.
https://seekingalpha.com/news/3581714-biocryst-launches-compassionate-use-program-for-berotralstat-for-hae
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.